Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the UK / NCT07666828
Recruiting Not applicable

Evaluation of Three Neuromuscular Electrical Stimulation Foot Pad Programmes on Lower Limb Haemodynamics in Healthy Adults

NCT07666828 · tracked via the Priya Life Science UK tracker
Sponsor
Joey Porter
Phase
Not applicable
Started
2026-09-22
Last updated
2026-09-25

Condition(s) studied

Healthy

Investigational drug(s) / intervention(s)

MedicP1PM7

Medic: The Medic programme is a currently marketed neuromuscular electrical stimulation (NMES) foot pad programme. It delivers electrical stimulation through the soles of the feet, via a commercially available NMES medical device, to induce lower limb muscle contractions and improve blood circulation during use.

P1: Programme 1 (P1) is an investigational NMES foot pad programme that incorporates a modified stimulation pattern designed to reduce muscle adaptation during a 30-minute stimulation session while maintaining the same intended purpose and mode of action as the marketed programme.

PM7: Personalised Medic v7 (PM7) is an investigational NMES foot pad programme that incorporates a modulation function intended to optimise the haemodynamic response during stimulation while maintaining the same intended purpose and mode of action as the marketed programme.

Study summary

The goal of this clinical investigation is to evaluate the performance of three neuromuscular electrical stimulation (NMES) foot pad programmes in healthy adults. It will also learn about how well the NMES programmes are tolerated.

The main questions it aims to answer are:

* Do two newly-developed NMES programmes ('P1' and 'PM7') increase lower limb blood flow more than the existing 'Medic' NMES programme during use?
* How do the programmes compare in terms of user discomfort and muscle oxygenation during use?

Researchers will compare the P1 and PM7 programmes with the existing Medic programme to determine whether the new programmes produce greater improvements in lower limb haemodynamics during device use.

Participants will:

* Attend four study visits at a single research site.
* Complete 1 familiarisation visit and 3 testing visits, with 12 hours to 7 days between visits.
* Use all three NMES programmes once in a randomised order.
* Receive 30 minutes of NMES during each testing visit.
* Undergo blood flow and muscle oxygenation measurements during each test.
* Complete questionnaires about discomfort and their experience using the device.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Healthy * Age 18 or over * Ability to communicate in English and provide informed consent Exclusion Criteria: * Lack of capacity to provide informed consent * Electronic implanted device (e.g. cardiac pacemaker) * Pregnancy or intending to become pregnant during the study period * Currently being treated for or have symptoms of an existing deep vein thrombosis (DVT) * Diagnosis of vascular disease or disorder * Terminal illness * Neurological disorders (e.g. epilepsy) * Musculoskeletal injury/disorders (e.g. recent injury or surgery) * Skin conditions (e.g. eczema or open wounds near plantar surface of the foot) * Cardiovascular conditions (e.g. arrhythmia or uncontrolled hypertension) * Diabetes mellitus with neuropathy.

Primary outcome measure(s)

  • Change in blood volume flow at the superficial femoral artery (SFA) — Throughout a 10-minute baseline, the 30-minute stimulation session and 8-minute post-stimulation period.
    Change in blood volume flow from baseline at the superficial femoral artery during a single 30-minute neuromuscular electrical stimulation (NMES) programme. Blood volume flow will be measured using Doppler ultrasound and compared between the Medic, P1, and PM7 NMES programmes.

Trial sites (1)

FacilityCityRegionStatus
The Lightbox Bracknell Berkshire Recruiting

Other trials for the same condition

Reconfirming the Safety and Performance of the Glyconics-DS System in Known Populations With and Without Diabetes Active, not recruiting
BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies Recruiting
A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY4066708 in Healthy Participants Recruiting
Safety, PK/PD, and Immunogenicity Study of SC ALXN2030 in Healthy Participants Active, not recruiting
A Study in People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07666828 on ClinicalTrials.gov ↗ ← All trials in the UK